2020 年第 12 期 第 15 卷

宫颈癌的免疫治疗研究进展

Research progress on immunotherapy of cervical cancer

作者：张唯一王铭洋李亚里

英文作者：Zhang Weiyi Wang Mingyang Li Yali

单位：中国人民解放军总医院第一医学中心妇产科，北京100853

英文单位：Department of Obestetrics and Gynecology First Medical Center Chinese PLA General Hospital Beijing 100853 China

关键词：宫颈癌；免疫治疗；人乳头瘤病毒疫苗；免疫检查点抑制剂

英文关键词：Cervicalcancer;Immunotherapy;Humanpapillomavirusvaccine;Immunecheckpointinhibitor

• 摘要：

• 宫颈癌是最常见的妇科恶性肿瘤，严重威胁女性健康，其发生与人乳头瘤病毒（HPV）的持续感染密切相关。随着分子生物学与免疫学研究的进展，HPV疫苗已在宫颈癌预防方面取得卓越成效，免疫治疗成为宫颈癌尤其是晚期及复发癌治疗的新模式。针对手术及放化疗治疗不理想的进展期或复发性宫颈癌，目前许多研究均在探索免疫治疗的安全性、效应性，主要研究方向包括标准治疗同期加用免疫治疗、单独使用免疫治疗、联合抗血管治疗或多种免疫治疗药物联用，以及新型 HPV 预防性疫苗的研究。本文对疫苗免疫治疗、过继细胞免疫治疗、树突状细胞免疫治疗和免疫检查点抑制剂等宫颈癌免疫治疗的进展进行综述。

• Cervical cancer is the most common gynecological tumor and it is a serious threat to women′s health. The occurrence is closely related to the persistent infection of human papillomavirus (HPV). With the progress of molecular biology and immunology, HPV vaccine achieved excellent results in the prevention of cervical cancer, and immunotherapy became a new treatment model for cervical cancer, especially for advanced and recurrent cancer. Many studies are currently exploring the safety and effectiveness for the treatment of advanced or recurrent cervical cancer that is not ideal for surgery, radiotherapy and chemotherapy. The main research directions include standard treatment with immunotherapy simultaneously, or immunotherapy alone. This article briefly reviews the progress of cervical cancer immunotherapy such as vaccine immunotherapy, adoptive cell immunotherapy, dendritic cell immunotherapy and immune checkpoint inhibitors.